Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maurice Pérol

Showing results (1-10 of 117) with videos related to

Pageof 12
Sort By:
Bulletin Du Cancer|September 13, 2007
[Angiogenesis and lung cancer]Maurice Pérol, Dominique Arpin
Future Oncology (London, England)|October 27, 2016
Alectinib for treatment of ALK-positive non-small-cell lung cancerVirginie Avrillon, Maurice Pérol
Bulletin Du Cancer|March 28, 2025
[First line treatment of non-oncogene-addicted metastatic non-small cell lung cancer]Romane Gille, Maurice Pérol
Presse Medicale (Paris, France : 1983)|February 26, 2011
[Maintenance therapy in advanced non-small cell lung cancer: A new paradigm?]Maurice Pérol, Dominique Arpin
Expert Opinion on Investigational Drugs|May 26, 2025
Clinical progress of B7-H3 targeted antibody drug conjugate ifinatamab deruxtecan for small-cell lung cancerMylène Wespiser, Romane Gille, Maurice Pérol
Expert Review of Anticancer Therapy|October 1, 2016
The safety and efficacy of ramucirumab in combination with docetaxel in the treatment of lung cancerValérie Paulus, Virginie Avrillon, Maurice Pérol
Expert Review of Anticancer Therapy|July 20, 2021
The safety and efficacy of erlotinib and ramucirumab combination in EGFR-mutant non-small-cell lung cancerMaxime Boussageon, Aurélie Swalduz, Maurice Pérol
Frontiers in Oncology|February 18, 2026
<i>ROS1</i>-positive non-small cell lung cancer: from genomics to treatment decisionsMylène Wespiser, Romane Gille, Maurice Pérol
Current Drug Targets|October 21, 2009
The role of pemetrexed in lung adenocarcinoma, mixed subtype with bronchioloalveolar carcinoma featuresMichael Duruisseaux, Jacques Cadranel, Maurice Pérol, et al.
La Revue Du Praticien|June 23, 2021
["Treatment of lung cancer with immune checkpoints inhibitors"]Mehdi Lamkhioued, Margaux Dupont, Pauline Leriche, et al.
Pageof 12

Showing results (1-10 of 117) with videos related to

Sort By:
Pageof 12
Bulletin Du Cancer|September 13, 2007
[Angiogenesis and lung cancer]Maurice Pérol, Dominique Arpin
Future Oncology (London, England)|October 27, 2016
Alectinib for treatment of ALK-positive non-small-cell lung cancerVirginie Avrillon, Maurice Pérol
Bulletin Du Cancer|March 28, 2025
[First line treatment of non-oncogene-addicted metastatic non-small cell lung cancer]Romane Gille, Maurice Pérol
Presse Medicale (Paris, France : 1983)|February 26, 2011
[Maintenance therapy in advanced non-small cell lung cancer: A new paradigm?]Maurice Pérol, Dominique Arpin
Expert Opinion on Investigational Drugs|May 26, 2025
Clinical progress of B7-H3 targeted antibody drug conjugate ifinatamab deruxtecan for small-cell lung cancerMylène Wespiser, Romane Gille, Maurice Pérol
Expert Review of Anticancer Therapy|October 1, 2016
The safety and efficacy of ramucirumab in combination with docetaxel in the treatment of lung cancerValérie Paulus, Virginie Avrillon, Maurice Pérol
Expert Review of Anticancer Therapy|July 20, 2021
The safety and efficacy of erlotinib and ramucirumab combination in EGFR-mutant non-small-cell lung cancerMaxime Boussageon, Aurélie Swalduz, Maurice Pérol
Frontiers in Oncology|February 18, 2026
<i>ROS1</i>-positive non-small cell lung cancer: from genomics to treatment decisionsMylène Wespiser, Romane Gille, Maurice Pérol
Current Drug Targets|October 21, 2009
The role of pemetrexed in lung adenocarcinoma, mixed subtype with bronchioloalveolar carcinoma featuresMichael Duruisseaux, Jacques Cadranel, Maurice Pérol, et al.
La Revue Du Praticien|June 23, 2021
["Treatment of lung cancer with immune checkpoints inhibitors"]Mehdi Lamkhioued, Margaux Dupont, Pauline Leriche, et al.
Pageof 12